[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2019001391A - N-(fenilsulfonil)benzamidas y compuestos relacionados como inhibidores de bcl-2. - Google Patents

N-(fenilsulfonil)benzamidas y compuestos relacionados como inhibidores de bcl-2.

Info

Publication number
MX2019001391A
MX2019001391A MX2019001391A MX2019001391A MX2019001391A MX 2019001391 A MX2019001391 A MX 2019001391A MX 2019001391 A MX2019001391 A MX 2019001391A MX 2019001391 A MX2019001391 A MX 2019001391A MX 2019001391 A MX2019001391 A MX 2019001391A
Authority
MX
Mexico
Prior art keywords
benzamides
phenylsulfonyl
bcl
inhibitors
related compounds
Prior art date
Application number
MX2019001391A
Other languages
English (en)
Inventor
Wang Shaomeng
Chen Jianyong
Original Assignee
Univ Michigan Regents
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan Regents filed Critical Univ Michigan Regents
Publication of MX2019001391A publication Critical patent/MX2019001391A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La presente divulgación proporciona compuestos que tienen la Fórmula I-A: (ver Fórmula) y sus sales y solvatos aceptables desde el punto de vista farmacéutico, en donde A, X1, X2, X3 R1a, R1b, E, y (ver Símbolo) son como se definen en la información de la memoria descriptiva. La presente divulgación también proporciona compuestos de la Fórmula I-A para usar en el tratamiento de una enfermedad, trastorno o afección que responda a la inhibición de la proteína Bcl-2, como el cáncer.
MX2019001391A 2016-08-05 2017-08-04 N-(fenilsulfonil)benzamidas y compuestos relacionados como inhibidores de bcl-2. MX2019001391A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662371504P 2016-08-05 2016-08-05
US201762454101P 2017-02-03 2017-02-03
PCT/US2017/045428 WO2018027097A1 (en) 2016-08-05 2017-08-04 N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors

Publications (1)

Publication Number Publication Date
MX2019001391A true MX2019001391A (es) 2019-06-06

Family

ID=59677319

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019001391A MX2019001391A (es) 2016-08-05 2017-08-04 N-(fenilsulfonil)benzamidas y compuestos relacionados como inhibidores de bcl-2.
MX2020013014A MX2020013014A (es) 2016-08-05 2019-01-31 N-(fenilsulfonil)benzamidas y compuestos relacionados como inhibidores de bcl-2.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020013014A MX2020013014A (es) 2016-08-05 2019-01-31 N-(fenilsulfonil)benzamidas y compuestos relacionados como inhibidores de bcl-2.

Country Status (26)

Country Link
US (3) US10829488B2 (es)
EP (3) EP4129999A1 (es)
JP (2) JP6651180B2 (es)
KR (2) KR102429704B1 (es)
CN (2) CN110483501B (es)
AU (2) AU2017305508B2 (es)
BR (1) BR112019001666A2 (es)
CA (1) CA3031419C (es)
CY (1) CY1123859T1 (es)
DK (1) DK3494115T3 (es)
ES (1) ES2849959T3 (es)
HR (1) HRP20202073T1 (es)
HU (1) HUE053414T2 (es)
IL (2) IL264059B (es)
LT (1) LT3494115T (es)
MX (2) MX2019001391A (es)
PE (1) PE20190711A1 (es)
PH (1) PH12019500231A1 (es)
PT (1) PT3494115T (es)
RS (1) RS61821B1 (es)
RU (3) RU2744358C2 (es)
SA (1) SA519401020B1 (es)
SG (2) SG10201913643YA (es)
SI (1) SI3494115T1 (es)
WO (1) WO2018027097A1 (es)
ZA (2) ZA201900240B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11001582B2 (en) * 2016-03-10 2021-05-11 Assia Chemical Industries Ltd. Solid state forms of Venetoclax and processes for preparation of Venetoclax
MX2019001391A (es) * 2016-08-05 2019-06-06 Univ Michigan Regents N-(fenilsulfonil)benzamidas y compuestos relacionados como inhibidores de bcl-2.
CN110177788B (zh) 2017-01-07 2023-03-24 重庆复创医药研究有限公司 作为bcl-2选择性凋亡诱导剂的化合物
MX2019012434A (es) 2017-04-18 2019-12-11 Shanghai Fochon Pharmaceutical Co Ltd Agentes inductores de apoptosis.
AU2019264475B2 (en) 2018-04-29 2024-09-26 Beigene, Ltd. Bcl-2 inhibitors
EP3672591B1 (en) * 2018-07-31 2024-02-14 Ascentage Pharma (Suzhou) Co., Ltd. Synergistic antitumor effect of bcl-2 inhibitor combined with rituximab and/or bendamustine or bcl-2 inhibitor combined with chop
EP3672595B1 (en) * 2018-07-31 2021-07-21 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases
CA3094449C (en) * 2018-07-31 2023-02-28 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of bcl-2 inhibitor and mdm2 inhibitor and use thereof in the prevention and/or treatment of diseases
CN114522167A (zh) * 2018-07-31 2022-05-24 苏州亚盛药业有限公司 Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途
EP3706741A4 (en) * 2018-11-23 2022-03-30 Ascentage Pharma (Suzhou) Co., Ltd. PHARMACEUTICAL COMPOSITION AND USE THEREOF
TWI770503B (zh) * 2019-05-13 2022-07-11 大陸商蘇州亞盛藥業有限公司 用於預測bcl-2/bcl-xl抑制劑對癌症的功效的方法和組合物
WO2021110097A1 (en) 2019-12-03 2021-06-10 Ascentage Pharma (Suzhou) Co., Ltd. N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
TW202114692A (zh) * 2019-07-02 2021-04-16 大陸商蘇州亞盛藥業有限公司 一種含有mTOR抑制劑的藥物組合及其應用
TW202114664A (zh) * 2019-07-31 2021-04-16 大陸商蘇州亞盛藥業有限公司 Ｂｃｌ－２／Ｂｃｌ－ｘＬ抑制劑與化療藥的組合產品及其在預防和／或治療疾病中的用途
TW202134239A (zh) * 2019-11-27 2021-09-16 大陸商蘇州亞盛藥業有限公司 用於預測靶向細胞凋亡途徑的化合物的抗癌功效的方法和組合物
EP4069233A4 (en) * 2019-12-04 2024-03-13 Ascentage Pharma (Suzhou) Co., Ltd. PHARMACEUTICAL COMBINATION AND USE THEREOF
US20230041515A1 (en) 2019-12-06 2023-02-09 Loxo Oncology, Inc. Dosing of a bruton's tyrosine kinase inhibitor
CN113354636B (zh) * 2020-03-06 2022-08-09 苏州亚盛药业有限公司 N-(苯基磺酰基)苯甲酰胺类化合物或其盐、溶剂合物的结晶形式或无定形形式
US20230128137A1 (en) * 2020-03-12 2023-04-27 Medshine Discovery Inc. Benzo five-membered cyclic compound
WO2021227763A1 (en) * 2020-05-14 2021-11-18 Ascentage Pharma (Suzhou) Co., Ltd. Hplc analysis method for n- (phenylsulfonyl) benzamide compound
WO2022002178A1 (en) * 2020-07-01 2022-01-06 Ascentage Pharma (Suzhou) Co., Ltd. Methods for synthesizing n-(phenylsulfonyl)benzamide compounds and intermediates thereof
CN111537654B (zh) * 2020-07-07 2020-11-10 上海亚盛医药科技有限公司 N-(苯基磺酰基)苯甲酰胺化合物的hplc分析方法
TW202214565A (zh) * 2020-07-10 2022-04-16 大陸商江蘇恆瑞醫藥股份有限公司 磺醯苯甲醯胺類衍生物及其偶聯物、其製備方法及其應用
CN114057728A (zh) * 2020-08-06 2022-02-18 北京诺诚健华医药科技有限公司 作为bcl-2抑制剂的杂环化合物
WO2022037683A1 (en) * 2020-08-21 2022-02-24 Ascentage Pharma (Suzhou) Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
CN114073707A (zh) * 2020-08-21 2022-02-22 苏州亚盛药业有限公司 治疗系统性红斑狼疮的组合物和方法
CN114533677A (zh) * 2020-11-25 2022-05-27 苏州亚盛药业有限公司 固体分散体、制剂、其制备方法及其应用
WO2022143602A1 (en) * 2020-12-28 2022-07-07 Ascentage Pharma (Suzhou) Co., Ltd. Methods of treating multiple sclerosis
JP2024504542A (ja) * 2021-02-01 2024-02-01 アセンテージ ファーマ（スーチョウ）カンパニー，リミティド Ｂｃｌ－２阻害剤としてのスルホニルベンズアミド誘導体
WO2022216942A1 (en) 2021-04-07 2022-10-13 Dana-Farber Cancer Institute, Inc. Compositions and methods for the treatment of cancer
CN117957018A (zh) 2021-08-02 2024-04-30 苏州亚盛药业有限公司 一种药物组合及其用途
CN115260191B (zh) * 2022-09-29 2022-12-27 上海睿跃生物科技有限公司 哌啶类化合物及其制备方法和应用
EP4421075A1 (en) * 2023-02-27 2024-08-28 KRKA, d.d., Novo mesto Process for the preparation of venetoclax and intermediates used therein
WO2024184233A1 (en) 2023-03-03 2024-09-12 Ionctura Sa Combination of roginolisib and bcl-2 inhibitor in the treatment of haematological malignancy

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1021343A (en) 1912-01-17 1912-03-26 M A N Mfg Company Locking-clamp.
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US7767684B2 (en) * 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
US8624027B2 (en) 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
JP5277168B2 (ja) 2006-09-05 2013-08-28 アボット・ラボラトリーズ 血小板過剰を治療するｂｃｌインヒビター
WO2008070663A2 (en) 2006-12-04 2008-06-12 Abbott Laboratories Companion diagnostic assays for cancer therapy
UA108193C2 (uk) * 2008-12-04 2015-04-10 Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
EP3101019A1 (en) 2008-12-05 2016-12-07 AbbVie Inc. Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
CN104945311A (zh) * 2009-01-19 2015-09-30 Abbvie公司 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂
US9045800B2 (en) 2009-02-11 2015-06-02 Abbvie Inc. Methods and compositions for identifying, classifying and monitoring subject having Bcl-2 family inhibitor-resistant tumors and cancers
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
AR076705A1 (es) * 2009-05-26 2011-06-29 Abbott Lab Agentes inductores de la apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes
TWI520960B (zh) * 2010-05-26 2016-02-11 艾伯維有限公司 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
NZ608274A (en) * 2010-10-29 2015-05-29 Abbvie Inc Solid dispersions containing an apoptosis-inducing agent
NZ610151A (en) 2010-11-23 2015-06-26 Abbvie Inc Salts and crystalline forms of an apoptosis-inducing agent
TWI620736B (zh) 2010-11-23 2018-04-11 艾伯維巴哈馬有限公司 使用選擇性ｂｃｌ-２抑制劑之治療方法
WO2017117416A1 (en) 2015-12-30 2017-07-06 Dexcom, Inc. System and method for factory calibration or reduced calibration of an indwelling sensor based on sensitivity profile
MX2019001391A (es) * 2016-08-05 2019-06-06 Univ Michigan Regents N-(fenilsulfonil)benzamidas y compuestos relacionados como inhibidores de bcl-2.

Also Published As

Publication number Publication date
US10829488B2 (en) 2020-11-10
IL282099A (en) 2021-05-31
KR102429704B1 (ko) 2022-08-04
BR112019001666A2 (pt) 2019-05-28
MX2020013014A (es) 2021-02-22
AU2017305508B2 (en) 2021-01-07
CY1123859T1 (el) 2022-05-27
US10221174B2 (en) 2019-03-05
AU2017305508A1 (en) 2019-02-07
SG10201913643YA (en) 2020-03-30
JP2019527705A (ja) 2019-10-03
KR20210107170A (ko) 2021-08-31
SG11201900135YA (en) 2019-02-27
AU2021202113B2 (en) 2022-08-18
US20180354950A1 (en) 2018-12-13
ES2849959T3 (es) 2021-08-24
NZ750100A (en) 2021-01-29
CN109311871A (zh) 2019-02-05
US20190315739A1 (en) 2019-10-17
ZA201908466B (en) 2020-05-27
KR20190035710A (ko) 2019-04-03
AU2021202113A1 (en) 2021-05-06
CA3031419A1 (en) 2018-02-08
IL264059A (en) 2019-01-31
SA519401020B1 (ar) 2022-03-16
EP3569601A2 (en) 2019-11-20
RU2722560C1 (ru) 2020-06-01
RS61821B1 (sr) 2021-06-30
EP3494115B1 (en) 2020-10-21
RU2020114660A (ru) 2020-06-19
US20210002277A1 (en) 2021-01-07
WO2018027097A1 (en) 2018-02-08
JP2020007311A (ja) 2020-01-16
IL282099B (en) 2022-03-01
CN109311871B (zh) 2020-02-28
IL264059B (en) 2021-05-31
US11718613B2 (en) 2023-08-08
PE20190711A1 (es) 2019-05-17
LT3494115T (lt) 2021-01-25
CN110483501A (zh) 2019-11-22
RU2744358C2 (ru) 2021-03-05
HUE053414T2 (hu) 2021-06-28
CN110483501B (zh) 2022-07-01
SI3494115T1 (sl) 2021-02-26
EP3569601A3 (en) 2019-11-27
EP4129999A1 (en) 2023-02-08
EP3494115A1 (en) 2019-06-12
EP3569601B1 (en) 2022-06-22
RU2020134802A (ru) 2022-04-25
PH12019500231A1 (en) 2019-07-29
JP6651180B2 (ja) 2020-02-19
JP7205903B2 (ja) 2023-01-17
DK3494115T3 (da) 2021-01-18
KR102376764B1 (ko) 2022-03-18
ZA201900240B (en) 2020-05-27
PT3494115T (pt) 2021-01-15
CA3031419C (en) 2021-08-24
HRP20202073T1 (hr) 2021-02-19
RU2020114660A3 (es) 2020-09-15

Similar Documents

Publication Publication Date Title
PH12019500231A1 (en) N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
CY1123810T1 (el) Τριφθορομεθυλ υποκατεστημενα πυραζολια ως αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα
WO2017176957A8 (en) Mdm2 protein degraders
PH12020500529A1 (en) Bicyclic heterocyclyl derivatives as irak4 inhibitors
MX2019002303A (es) Inhibidores de procesos metabolicos celulares.
PH12018501340A1 (en) Heterocyclic compounds as immunomodulators
MX2023006257A (es) Inhibidores de smyd.
MX2020012165A (es) Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cancer.
PH12016501338A1 (en) Indazole compounds as irak4 inhibitors
TR201901312T4 (tr) Mcl-1 proteinini inhibe eden tetrahidronaftalen türevleri.
MX2019009501A (es) Compuestos de amino piridina utiles como inhibidores de ssao.
EA201891526A2 (ru) Ингибиторы лизин-специфической деметилазы-1
AR103680A1 (es) Inhibidores selectivos de bace1
EA201591781A1 (ru) Химические соединения
PH12016502353A1 (en) Pharmaceutical composition
MX2018004664A (es) Antagonistas de ep4.
TW201613577A (en) Pharmaceutical combinations
PH12019500569A1 (en) Blood-brain barrier-penetrant dopamine-b-hydroxylase inhibitors
MX2021003732A (es) Inhibidores de menina de molécula pequeña.
MX2018014080A (es) Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia.
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
NZ750150A (en) Combination of histamine-3 receptor inverse agonists with acetylcholinesterase inhibitors
PH12019500368A1 (en) Inhibitors of cellular metabolic processes
EA202190930A1 (ru) Низкомолекулярные ингибиторы менина
NZ751515B2 (en) Inhibitors of cellular metabolic processes